Adolescent weight loss during treatment with olanzapine

Journal of Child and Adolescent Psychopharmacology

Volumn 14, Issue 4, 2005, Pages 617-620

  Cohen, Judith A ^a   Perel, James M ^b  

^a ALLEGHENY GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT; OLANZAPINE;

ADOLESCENT; ADOLESCENT DISEASE; AGGRESSION; ARTICLE; BIPOLAR DISORDER; BODY MASS; BODY WEIGHT DISORDER; CASE REPORT; DRUG MECHANISM; HUMAN; MALE; PATIENT COMPLIANCE; PSYCHOSIS; WEIGHT REDUCTION;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BODY MASS INDEX; CHILD; CHILD ABUSE, SEXUAL; DEPRESSIVE DISORDER, MAJOR; HUMANS; MALE; OBSESSIVE-COMPULSIVE DISORDER; WEIGHT LOSS;

EID: 12744273100     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2004.14.617     Document Type: Article

References (13)

1. Basile VS, Masellis M, McIntyre RS, Meltzer HY, Lieberman JA, Kennedy JL: Genetic dissection of atypical antipsychotic-induced weight gain: Novel preliminary data on the pharmacogenetic puzzle. J Clin Psychiatry 62(Suppl 23):46-66, 2001.
2. Blundell JE, Halford JCG: Serotonin and appetite regulation. CNS Drugs 9:473-495, 1998.
3. Casey DE, Zorn SH: The pharmacology of weight gain with antipsychotics. J Clin Psychiatry 62 (Suppl 7):4-10, 2001.
4. DeBellis MD, Baum AS, Birmaher B, Keshavan MS, Eccard CH, Boring AM: Developmental traumatology, part I: Biological stress symptoms. Biol Psychiatry 45:1259-1270, 1999.
5. deHaan L, van Amelsvoort T, Rosien M, Linszen D: Weight loss after switching from conventional olanzapine tablets to orally disintegrating olanzapine tablets. Psychopharmacology 175:389-390, 2004.
6. Kassahun K, Mattuz E, Nyhart E, Obermeyer B, Gillespie T, Murphy A: Disposition and biotransformation of the antipsychotic agent olanzapine on humans. Dr Metab Dispos 25:91-93, 1997.
7. Melkersson KI, Dahl ML: Relationship between levels of insulin or triglycerides and serum concentrations of the atypical antipsychotic clozapine and olanzapine in patients on treatment with therapeutic doses. Psychopharmacology 170:157-166, 2003.
8. 2C receptor gene and clozapine-induced weight gain. Am J Psychiatry 160:677-679, 2003.
9. Ring BJ, Catlow J, Lindsay TJ, Gillespie T, Roskos LK, Cerimele SP: Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine. J Pharmacol Exp Ther 276:658-666, 1996.
10. 2C receptor activation decreases appetite and body weight in obese subjects. Psychopharmacology 133:309-312, 1997.
11. Schatzberg AF, Rothschild AJ, Stahl JB, Bond TC, Rosenbaum AH, Lofgren SB: The dexamethasone suppression test: Identification of subtypes of depression. Am J Psychiatry 140:88-91, 1983.
12. 2C receptor gene. Neuroreport 7:169-172, 1995.
13. 2C receptor agonist mCPP, reduces body weight gain in rats over 28 days as a result of maintained hypophagia. Psychopharmacology 167:274-280, 2003.